9 research outputs found

    Another Shipment of Six Short-Period Giant Planets from TESS

    Get PDF
    We present the discovery and characterization of six short-period, transiting giant planets from NASA's Transiting Exoplanet Survey Satellite (TESS) -- TOI-1811 (TIC 376524552), TOI-2025 (TIC 394050135), TOI-2145 (TIC 88992642), TOI-2152 (TIC 395393265), TOI-2154 (TIC 428787891), & TOI-2497 (TIC 97568467). All six planets orbit bright host stars (8.9 <G< 11.8, 7.7 <K< 10.1). Using a combination of time-series photometric and spectroscopic follow-up observations from the TESS Follow-up Observing Program (TFOP) Working Group, we have determined that the planets are Jovian-sized (RP_{P} = 1.00-1.45 RJ_{J}), have masses ranging from 0.92 to 5.35 MJ_{J}, and orbit F, G, and K stars (4753 << Teff_{eff} << 7360 K). We detect a significant orbital eccentricity for the three longest-period systems in our sample: TOI-2025 b (P = 8.872 days, ee = 0.220±0.0530.220\pm0.053), TOI-2145 b (P = 10.261 days, ee = 0.1820.049+0.0390.182^{+0.039}_{-0.049}), and TOI-2497 b (P = 10.656 days, ee = 0.1960.053+0.0590.196^{+0.059}_{-0.053}). TOI-2145 b and TOI-2497 b both orbit subgiant host stars (3.8 << log\log g <<4.0), but these planets show no sign of inflation despite very high levels of irradiation. The lack of inflation may be explained by the high mass of the planets; 5.350.35+0.325.35^{+0.32}_{-0.35} MJ_{\rm J} (TOI-2145 b) and 5.21±0.525.21\pm0.52 MJ_{\rm J} (TOI-2497 b). These six new discoveries contribute to the larger community effort to use {\it TESS} to create a magnitude-complete, self-consistent sample of giant planets with well-determined parameters for future detailed studies.Comment: 20 Pages, 6 Figures, 8 Tables, Accepted by MNRA

    The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

    Get PDF
    Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

    KELT-22Ab: A Massive, Short-Period Hot Jupiter Transiting a Near-solar Twin

    No full text
    We present the discovery of KELT-22Ab, a hot Jupiter from the KELT-South survey. KELT-22Ab transits the moderately bright (V similar to 11.1) Sun-like G2V star TYC 7518-468-1. The planet has an orbital period of P = 1.3866529 +/- 0.0000027 days, a radius of R-P = 1.285(-0.071)(+0.12) R-J, and a relatively large mass of M-P = 3.47(-0.14)(+0.15), M-J. The star has R-star = 1.099(-0.046)(0.079) R-circle dot, M-star = 1.092(-0.041)(+0.045) M-circle dot, T-eff = 5767(-49)(+50) K, log g(star) = 4.393(-0.060)(+0.039) (cgs), and [m/H] = +0.259(-0.083)(+0.085); thus other than its slightly super-solar metallicity, it appears to be a near-solar twin. Surprisingly, KELT-22A exhibits kinematics and a Galactic orbit that are somewhat atypical for thin-disk stars. Nevertheless, the star is rotating rapidly for its estimated age, and shows evidence of chromospheric activity. Imaging reveals a slightly fainter companion to KELT-22A that is likely bound, with a projected separation of 6 '' (similar to 1400 au). In addition to the orbital motion caused by the transiting planet, we detect a possible linear trend in the radial velocity of KELT-22A, suggesting the presence of another relatively nearby body that is perhaps non-stellar. KELT-22Ab is highly irradiated (as a consequence of the small semimajor axis of a/R-star, and is mildly inflated. At such small separations, tidal forces become significant. The configuration of this system is optimal for measuring the rate of tidal dissipation within the host star. Our models predict that, due to tidal forces, the semimajor axis is decreasing rapidly, and KELT-22Ab is predicted to spiral into the star within the next Gyr

    KELT-22Ab: A Massive, Short-Period Hot Jupiter Transiting a Near-solar Twin

    No full text

    Faster Sensitivity Loss around Dense Scotomas than for Overall Macular Sensitivity in Stargardt Disease: ProgStar Report No. 14

    No full text

    The Changing Landscape for Stroke\ua0Prevention in AF

    No full text

    The Changing Landscape for Stroke Prevention in AF

    No full text
    corecore